B1SP fusion protein therapeutics, methods, and uses
AssigneeThe University of British Columbia
InventorsChristopher J. Ong, James William Peacock, Martin E. Gleave
Life of this patent
Estimating the term…
Abstract
Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include a sema domain, a structural stabilization domain; and a half life extending moiety.
Claims36
A fusion protein comprising:
- (a) a SEMA3C sema domain or Plexin B 1 sema domain;
- (b) a single Plexins-Semaphorins-Integrins domain (PSI domain);
- and
- (c) a half life extending moiety, provided that when the sema domain is from SEMA3C then the half-life extending moiety is albumin and provided that when the sema domain is from Plexin B 1 then the half-life extending moiety is a fragment crystallizable region (Fc region) and the Fc region forms a dimer,
- provided that when the sema domain is from SEMA3C the fusion protein lacks an immunoglobulin-like domain.
A pharmaceutical composition comprising a fusion protein in combination with a physiologically acceptable carrier, wherein the fusion protein comprises:
- (a) a SEMA3C sema domain or Plexin B1 sema domain;
- (b) a single Plexins-Semaphorins-Integrins domain (PSI domain);
- and
- (c) a half life extending moiety, provided that when the sema domain is from SEMA3C then the half-life extending moiety is albumin, and provided that when the sema domain is from Plexin B1 then the half-life extending moiety is a fragment crystallizable region (Fc region) and the Fc region forms a dimer,
- provided that when the sema domain is from SEMA3C the fusion protein lacks an immunoglobulin-like domain.
Dependencies are inferred from the claim text.